0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Updates |

Update in Oncology

Lowell E. Schnipper, MD
[+] Article and Author Information

Adapted for publication in Annals of Internal Medicine by Jennifer Fisher Wilson and Michael Berkwits, MD, MSCE.


From Beth Israel Deaconness Medical Center, Boston, Massachusetts.


Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Lowell E. Schnipper, MD, Division of Hematology/Oncology, Beth Israel Deaconness Medical Center, 330 Brookline Avenue, Boston, MA 02215; e-mail, lschnipp@bidmc.harvard.edu.


Ann Intern Med. 2007;147(11):775-782. doi:10.7326/0003-4819-147-11-200712040-00008
Text Size: A A A

This Update in Oncology reviews the most important articles relevant to oncology that were published in 2006. The Table summarizes changes to clinical practice that should emerge from these articles. They reflect improvement in the use of standard chemotherapy for ovarian and gastric cancers, guidance for managing patients with type II Lynch syndrome, possible new screening approaches for lung cancer, and application of targeted molecular therapies to important clinical problems.

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Overloking Oncological Terrain and oncological Real Risk, no paper is up-dated!
Posted on December 16, 2007
Sergio Stagnaro
Biophysical Semeiotics Research Laboratory
Conflict of Interest: None Declared

Sirs, the paper is really intriguing, obwohl I think not completely up-dated. In fact, ignoring or overlooking the existence of Oncological Terrain (http://www.semeioticabiofisica.it) as well as cancer inherited "real" risk, in a quantitative way, we cannot prevent and diagnose early cancer (1-4). Consequently, authors around the world are thinking "wrongly" that "all" individuals may be involved by malignancy, and as a consequence all individuals have urdergo to tumour marker assessement, therefore spending uselessly NHS money, and physician's energy and time, because physicians think that everybody can be involved by malignacy. As a matter of fact, e.g., a woman can be involved by Oncological Terrain, even with or without precise location of "inherited cancer real risk" in a well defined breast quadrant ("ab posse ad esse non licet illatio", Kant, Kritik der reinigen Vernunft) (5). I think that because congenital functional mitochondrial cytopathology is overlooked--a "conditio sine qua non" of the most frequent and dangerous human disorders, including malignancies-- current clinical researches are fundamentally biased. In other words, it does not consider the existence or assess the seriousness as well as the location of Congenital Acidosic Enzyme-Metabolic Histangiopathy (in my site), conditio sine qua non of both Oncological Terrain and, consequently camcer "real risk" (2-4). In fact, both environmental risk factors and every drug, including oestrogens, suggested as a risk factor for breast cancer, "could" influence some human biological functions and/or bring about different disorders, such as cancers, exclusively in relation to both the presence and intensity of CAEMH in a well-defined biological system. For instance, despite either the well-known negative influence of oral contraceptive use or the beneficial, positive effects of selective cyclooxygenase-2 (COX-2) inhibitors on breast oncogenesis (1) we have to consider the importance of the "genetic predispositions", i.e., Oncological Terrain, as far as the onset of a lot of disorders is concerned, including breast cancer. In conclusion, we need at first (i.e., starting whatever screening or research) to investigate the presence and intensity of CAEMH in the "tested" population, i.e. in "every", "single" patient, and soon thereafter assessing presence, intensity of the CAEMH-dependent, "Oncological Terrain", and the precise location of cancer congenital "real risk", both always develop on the basis of the above -mentioned congenital mitochondrial cytopathology. In fact, without this alteration of psycho- neuro-endocrine-immunological system, oncogenesis is not possible, as allows me to state a 51-year-long clinical experience with Biophysical Semeiotics, Single Patient Based Medicine theory is based on (6). Finally, these pathological conditions are characterized by microcirculatory remodelling, wherein a central role is played by newborn-pathological, type I, "typical" a), i.e., oncological subtype Endoarteriolar Blocking Devices.

1) Stagnaro-Neri M., Stagnaro S. Introduzione alla Semeiotica Biofisica. Il Terreno Oncologico. Travel Factory, Roma, 2004. http://www.travelfactory.it 2) Stagnaro Sergio. There is another clinical, and overlooked tool, reliable in breast cancer prognosis evaluation http://www.biomedcentral.com/1471-2407/5/70/comments#204473 2005

3) Sergio Stagnaro Mitochondrial Bed-Side Evaluation: a new Way in the War against Cancer (21 December 2005). Cancer Cell International http://www.cancerci.com/content/5/1/34/comments#218502 4) Stagnaro S. Stagnaro S., Stagnaro-Neri M., La Melatonina nella Terapia del Terreno Oncologico e del "Reale Rischio" Oncologico. Travel Factory, Roma, 2004. http://www.travelfactory.it/semeiotica_biofisica_2.htm 5) Stagnaro-Neri M., Stagnaro S. Cancro della mammella: prevenzione primaria e diagnosi precoce con la percussione ascoltata. Gazz. Med. It. "“ Arch. Sc. Med. 152, 447, 1993 6) Stagnaro S., Stagnaro-Neri M., Single Patient Based Medicine.La Medicina Basata sul Singolo Paziente: Nuove Indicazioni della Melatonina. Travel Factory, Roma, 2005. http://www.travelfactory.it/libro_singlepatientbased.htm 7) Stagnaro Sergio. Clinical tool reliable in bedside early recognizing pancreas tumour, both benign and malignant. World Journal of Surgical Oncology 2005, 3:62 doi:10.1186/1477-7819-3-62, 2005 8) Stagnaro Sergio. Bed-Side Evaluating Breast Cancer Real Risk. World Journal of Surgical Oncology. 2005, 3:67 doi:10.1186/1477-7819-3-67. 2005 2005 9) Stagnaro Sergio. Mitochondrial Bed-Side Evaluation: a new Way in the War against Cancer (21 December 2005). Cancer Cell International http://www.cancerci.com/content/5/1/34/comments#218502 2005 10) Stagnaro Sergio. Cancer Risk Factors and Oncological Terrain. 2006. http://www.wjso.com/content/4/1/74/comments#247528 2006 11) Stagnaro Sergio. Without Oncological Terrain oncogenesis is not possible. CMAJ. 23 March 2007 http://www.cmaj.ca/cgi/eletters/176/5/646 12) Stagnaro Sergio. GPs , Biophysical Semeiotics, and bedside cancer diagnosis. 08 July 2007, International Seminar of Surgical Oncology, http://www.issoonline.com/content/4/1/11/comments#281539 , 2007 13) Stagnaro Sergio. Bedside Evaluation Tobacco's actions on Biological Systems. The Lancet, October 13, 2007, http://www.thelancet.com/journals/lancet/article/PIIS0140673607614822/comments?action=view&totalComments=2#1286 2007 14) Stagnaro Sergio. Oncological Terrain and Inherited Oncological Real Risk: New Way in Malignancy Primary Prevention and early Diagnosis. International Seminars in Surgical Oncology, 2007. http://www.issoonline.com/content/4/1/25/comments#290565 15) Stagnaro Sergio. Bedside Biophysical-Semeiotic Diagnosis of Breast Cancer, since initial Stage. International Seminars in Surgical Oncology 2007, http://www.issoonline.com/content/4/1/21/comments

Conflict of Interest:

None declared

Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)